FDA approves the first immunotherapy regimen for platinum-resistant ovarian cancer with a proven survival benefit
Evidence stage: Later-Stage HumanRegulatory status: FDA Approved
In the randomized, phase 3 ENGOT-ov65/KEYNOTE-B96 trial, adding pembrolizumab to paclitaxel chemotherapy significantly improved BOTH progression-free survival (8.3 vs 7.2 months) AND overall survival (18.2 vs 14.0 months) in patients…
Primary source cited
Last reviewed